Oncogenic role of MiR-130a in oral squamous cell carcinoma.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 04 2021
Historique:
received: 17 12 2020
accepted: 26 03 2021
entrez: 9 4 2021
pubmed: 10 4 2021
medline: 9 11 2021
Statut: epublish

Résumé

Aberrant activation of the PI3K/AKT/mTOR pathway is attributed to the pathogenesis of oral squamous cell carcinoma (OSCC). In recent years, increasing evidence suggests the involvement of microRNAs (miRNAs) in oral carcinogenesis by acting as tumor suppressors or oncogenes. TSC1, as a component of the above pathway, regulates several cellular functions such as cell proliferation, apoptosis, migration and invasion. Downregulation of TSC1 is reported in oral as well as several other cancers and is associated with an unfavourable clinical outcome in patients. Here we show that oncogenic miR-130a binds to the 3'UTR of TSC1 and represses its expression. MiR-130a-mediated repression of TSC1 increases cell proliferation, anchorage independent growth and invasion of OSCC cells, which is dependent on the presence of the 3'UTR in TSC1. We observe an inverse correlation between the expression levels of miR-130a and TSC1 in OSCC samples, suggesting that their interaction is physiologically relevant. Delivery of antagomiR-130a to OSCC cells results in a significant decrease in xenograft size. Taken together, the findings of the study indicate that miR-130a-mediated TSC1 downregulation is not only a novel mechanism in OSCC, but also the restoration of TSC1 levels by antagomiR-130a may be a potential therapeutic strategy for the treatment of OSCC.

Identifiants

pubmed: 33833339
doi: 10.1038/s41598-021-87388-4
pii: 10.1038/s41598-021-87388-4
pmc: PMC8032739
doi:

Substances chimiques

MIRN130 microRNA, human 0
MicroRNAs 0
TSC1 protein, human 0
Tuberous Sclerosis Complex 1 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7787

Références

J Pathol. 2013 May;230(1):17-27
pubmed: 23401075
Mol Cancer. 2014 Jan 10;13:6
pubmed: 24410957
Gut. 2017 Aug;66(8):1496-1506
pubmed: 27974549
In Vitro Cell Dev Biol Anim. 2018 Dec;54(10):715-724
pubmed: 30341633
Oncol Lett. 2013 May;5(5):1639-1642
pubmed: 23761828
Oncogene. 2000 Dec 14;19(54):6306-16
pubmed: 11175345
Dev Cell. 2015 Mar 9;32(5):617-30
pubmed: 25727005
J Surg Oncol. 2014 Jun;109(8):812-7
pubmed: 24615476
Mol Ther. 2018 Oct 3;26(10):2466-2475
pubmed: 30120059
Am J Med Sci. 2010 Nov;340(5):385-8
pubmed: 20625274
Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):746-754
pubmed: 29739748
Cell Death Differ. 2019 Sep;26(9):1782-1795
pubmed: 30518907
Front Immunol. 2018 May 09;9:966
pubmed: 29867948
Oncotarget. 2015 Oct 20;6(32):33269-78
pubmed: 26375442
Cell. 2007 Aug 10;130(3):440-55
pubmed: 17693255
Cell Physiol Biochem. 2018;50(5):1804-1814
pubmed: 30396185
Onco Targets Ther. 2017 Aug 03;10:3893-3905
pubmed: 28831264
Oncotarget. 2016 Apr 19;7(16):21865-74
pubmed: 26967564
Cancer Res. 2010 Nov 1;70(21):8937-47
pubmed: 20940396
Sci Rep. 2015 Dec 07;5:17621
pubmed: 26639757
Oncotarget. 2015 Jun 20;6(17):14993-5007
pubmed: 25915427
Oncotarget. 2017 Dec 15;9(2):2017-2027
pubmed: 29416749
BMC Mol Biol. 2008 Apr 10;9:34
pubmed: 18400113
Oncol Lett. 2019 Jan;17(1):729-738
pubmed: 30655824
PLoS One. 2013 May 08;8(5):e62589
pubmed: 23667495
Biomed Pharmacother. 2015 Apr;71:53-7
pubmed: 25960215
J Biol Chem. 2013 Jan 4;288(1):608-18
pubmed: 23166327
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6
pubmed: 12271141
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8762-7
pubmed: 11438694
Nat Med. 2013 Mar;19(3):351-7
pubmed: 23435171
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Hum Mol Genet. 2000 Jul 22;9(12):1721-7
pubmed: 10915759
J Biol Chem. 2003 Dec 19;278(51):51372-9
pubmed: 14551205
Oncol Rep. 2017 Sep;38(3):1613-1620
pubmed: 28713923
Mol Cell. 2012 Aug 24;47(4):535-46
pubmed: 22795129
PLoS One. 2013;8(1):e54503
pubmed: 23355874
Oncotarget. 2015 Sep 29;6(29):27097-112
pubmed: 26318033
BMC Cancer. 2008 Jun 06;8:163
pubmed: 18538015
Hum Mol Genet. 2006 Jan 15;15(2):287-97
pubmed: 16339216
Cell Death Differ. 2017 Dec;24(12):2089-2100
pubmed: 28800130
Nat Cell Biol. 2000 May;2(5):281-7
pubmed: 10806479
Nucleic Acids Res. 2014 Jun;42(10):6243-55
pubmed: 24748662
Oncol Rep. 2018 Jun;39(6):2473-2481
pubmed: 29658589
Oncol Rep. 2015 Sep;34(3):1153-61
pubmed: 26134263
Oncogene. 2010 Mar 18;29(11):1588-97
pubmed: 19966866
Ann Surg Oncol. 2014 Dec;21 Suppl 4:S634-9
pubmed: 24770722
Front Mol Neurosci. 2017 May 30;10:160
pubmed: 28611587
Sci Rep. 2017 Apr 11;7(1):834
pubmed: 28400571
Science. 1997 Aug 8;277(5327):805-8
pubmed: 9242607
Cell Death Dis. 2018 Sep 11;9(9):917
pubmed: 30206227
Eur J Cancer. 2005 Jul;41(11):1628-36
pubmed: 15951164

Auteurs

Karthik Mallela (K)

Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012, India.

Swamy Shivananda (S)

HCG-Bangalore Institute of Oncology, Bangalore, 560027, India.

Kodaganur S Gopinath (KS)

HCG-Bangalore Institute of Oncology, Bangalore, 560027, India.

Arun Kumar (A)

Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012, India. arunk@iisc.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH